BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26998706)

  • 1. Alvocidib (flavopiridol) for the treatment of chronic lymphocytic leukemia.
    Wiernik PH
    Expert Opin Investig Drugs; 2016 Jun; 25(6):729-34. PubMed ID: 26998706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia.
    Zeidner JF; Karp JE
    Leuk Res; 2015 Dec; 39(12):1312-8. PubMed ID: 26521988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
    Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
    Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
    Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
    Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
    Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
    Mahoney E; Lucas DM; Gupta SV; Wagner AJ; Herman SE; Smith LL; Yeh YY; Andritsos L; Jones JA; Flynn JM; Blum KA; Zhang X; Lehman A; Kong H; Gurcan M; Grever MR; Johnson AJ; Byrd JC
    Blood; 2012 Aug; 120(6):1262-73. PubMed ID: 22740450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flavopiridol in the treatment of chronic lymphocytic leukemia.
    Christian BA; Grever MR; Byrd JC; Lin TS
    Curr Opin Oncol; 2007 Nov; 19(6):573-8. PubMed ID: 17906454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flavopiridol in chronic lymphocytic leukemia: a concise review.
    Christian BA; Grever MR; Byrd JC; Lin TS
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S179-85. PubMed ID: 19778838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
    Stephens DM; Ruppert AS; Maddocks K; Andritsos L; Baiocchi R; Jones J; Johnson AJ; Smith LL; Zhao Y; Ling Y; Li J; Phelps MA; Grever MR; Byrd JC; Flynn JM
    Leuk Res; 2013 Oct; 37(10):1195-9. PubMed ID: 23867058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Blachly JS; Byrd JC; Grever M
    Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
    Lin TS
    Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flavopiridol downregulates the expression of both the inducible NO synthase and p27(kip1) in malignant cells from B-cell chronic lymphocytic leukemia.
    Billard C; Kern C; Tang R; Ajchenbaum-Cymbalista F; Kolb JP
    Leukemia; 2003 Dec; 17(12):2435-43. PubMed ID: 14523476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
    Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
    Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autophagy and ER stress play an essential role in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol.
    Mahoney E; Byrd JC; Johnson AJ
    Autophagy; 2013 Mar; 9(3):434-5. PubMed ID: 23422081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
    Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
    Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flavopiridol-induced iNOS downregulation during apoptosis of chronic lymphocytic leukemia cells is caspase-dependent.
    Billard C; Menasria F; Quiney C; Faussat AM; Kolb JP
    Leuk Res; 2008 May; 32(5):755-60. PubMed ID: 17981326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.
    Senderowicz AM; Headlee D; Stinson SF; Lush RM; Kalil N; Villalba L; Hill K; Steinberg SM; Figg WD; Tompkins A; Arbuck SG; Sausville EA
    J Clin Oncol; 1998 Sep; 16(9):2986-99. PubMed ID: 9738567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.
    Zhai S; Senderowicz AM; Sausville EA; Figg WD
    Ann Pharmacother; 2002 May; 36(5):905-11. PubMed ID: 11978170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
    Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
    J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
    Awan FT; Jones JA; Maddocks K; Poi M; Grever MR; Johnson A; Byrd JC; Andritsos LA
    Ann Hematol; 2016 Jun; 95(7):1137-43. PubMed ID: 27118540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.